DEXRAZOXANE, DOXORUBICIN & ESCALATING DOSES OF PACLITAXEL IN ADVANCED BREAST CA

右雷佐生、阿霉素

• 批准号: 6246868
• 负责人: JAMES SPEYER
• 金额: $ 2.39万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-12 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6246868
• 关键词: antineoplastics; breast neoplasms; clinical research; clinical trial phase I; combination chemotherapy; doxorubicin; drug screening /evaluation; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; paclitaxel; pharmacokinetics

This Phase I trial will determine the maximum tolerable dose and response rate of paclitaxel that can be combined with doxorubicin and dexrazoxane with and without G-CSF. The effect of dexrazoxane on the pharmokinetics of paclitaxel used in combination with doxorubicin will be assessed. The maximum cumulative dose of doxorubicin that can be given when used in combination with dexrazoxane and paclitaxel will also be assessed.

这项I期试验将确定最大耐受剂量和反应